Australian researchers have developed a biomarker-derived model for predicting which patients with Crohn’s disease will benefit from early biologic therapy. The Crohn’s Immunomodulator CRP-Albumin (CICA) Index uses the readily available measures of an elevated CRP and low albumin to predict the likelihood of immunomodulator failure. A retrospective study of 410 adults with luminal Crohns’ disease ...
Australian biomarker model identifies Crohn’s patients for early biologic treatment
By Mardi Chapman
30 Sep 2020